RT Journal
T1 INvestigational heptavalent botulinum antitoxin (hbat) to replace licensed botulinum antitoxin ab and investigational botulinum antitoxin e
JF JAMA
JO JAMA
YR 2010
FD June 2
VO 303
IS 21
SP 2135
OP 2135
DO 
UL http://dx.doi.org/
AB 
CDC announces the availability of a new heptavalent botulinum antitoxin (HBAT, Cangene Corporation) through a CDC-sponsored Food and Drug Administration (FDA) Investigational New Drug (IND) protocol. HBAT replaces a licensed bivalent botulinum antitoxin AB and an investigational monovalent botulinum antitoxin E (BAT-AB and BAT-E, Sanofi Pasteur) with expiration of these products on March 12, 2010. As of March 13, 2010, HBAT became the only botulinum antitoxin available in the United States for naturally occurring noninfant botulism.